Navigation Links
BioSpecifics Announces Positive Results From Clinical Trial in Canine Lipomas
Date:1/6/2011

o BioSpecifics. If Auxilium chooses not to exercise this option, BioSpecifics plans to proceed with the development of its injectable collagenase for veterinary indications on its own.

About Chien-803 Clinical TrialThe trial will enroll 25 canines, each having two or more lipomas. To meet the primary endpoint an animal must achieve at least a 50% decrease in the drug-treated lipoma volume relative to baseline as measured by CT scan at 3 months post injection. The Company expects to announce top-line results from this trial in the second half of 2011.

Human Lipoma Study Results BioSpecifics previously conducted an open label study evaluating the safety and efficacy of injectable collagenase in the treatment of human lipoma. Eleven of the twelve subjects completed the follow up scheduled for the trial.  Patients in the study received a single injection of collagenase consisting of 1,000 units (0.058 mg) per centimeter diameter of the lipoma. Subjects were evaluated at baseline prior to the administration of study treatment and at one, three, seven and fourteen days, and one, three and six months post treatment to evaluate the overlying skin as well as the general area for untoward effects.  Results showed that there was an average reduction of lipoma size of 93% post treatment at six months.

About Canine LipomasLipomas are encapsulated fat deposits that occur under the skin. Lipomas that restrict motion in older dogs are a serious problem; the only proven therapy for this condition is surgical excision of the lipoma, which necessarily involves the use of general anesthesia; it has been estimated that up to 2% of sick dogs die as a complication of general anesthesia.(1)  Lipomas occur in 2.3% of the dog population,(2)  or in approximately 1.7 million dogs in the U.S.(3) (1) Brodbelt Vet J 2009 Dec; 182 (3): 375-6 (2) Lund JAVMA Vol. 214, No. 9, May 1, 1999(3) U.S. Pet Ownership & Demographics Sourcebook (2007 Editio
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioSpecifics Technologies Corp. to Present at UBS Global Life Sciences Conference
2. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 12th Annual Healthcare Conference
3. Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
4. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
6. BioSpecifics Technologies Corp. Stock Trading Halted Today
7. BioSpecifics Technologies Corp. To Present at BioCentury NewsMakers in the Biotech Industry Conference
8. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
9. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
11. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Research and Markets has announced the addition ... Market 2014-2018" report to their offering. ... the study of the gene and its functions and ... of proteomes or sets of proteins by using molecular ... mapping of genes and DNA sequencing to understand the ...
(Date:7/24/2014)... , July 24, 2014 SRI International ... with the National Institute of Allergy and Infectious Diseases ... conduct preclinical development of potential therapies for HIV infection ... to treat HIV and AIDS and the complications and ... microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... July 24, 2014 Three companies from ... in Livestrong’s Big C Competition. Out of 700 competition ... headed to the semi-final round. In this round twenty ... accelerator program, complete with mentoring from thought-leaders and medical ... part of the angelMD commitment to the Livestrong vision ...
(Date:7/24/2014)... 2014  Neogen Corporation (Nasdaq: NEOG ) ... potential revenue from new rodenticide research are premature. In ... on July 22, 2014, Neogen,s CEO commented about several ... "It was my intent Tuesday at our ... a new type of rodenticide, but certainly not to ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... 28 , - Guests Will ... , Staying healthy in these stressful ... Attitude Health Retreats early in 2009 may provide,participants with the ... A key component of the retreat ...
... XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , ... it received a Staff Determination Letter (the "Letter") from ... the staff of Nasdaq,s Listing Qualifications Department determined, using ... the Company,s American Depository Shares ("ADRs") would be delisted ...
... web based CTMS (Clinical Trial Management System), has ... deployed visit reports, site payments, sponsor portal and ... project will include integration to our electronic data ... as other innovative functional changes to the system ...
Cached Biology Technology:New Health Retreat Gives a Fresh Attitude Towards Disease Prevention 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 2AAIPharma Deploys Clinical Force CTMS (Clinical Trials Management System) 3
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... Scientists at The New York Stem Cell ... to creating a viable cell replacement therapy for ... , For the first time, NYSCF scientists generated ... samples of patients with primary progressive multiple sclerosis ... induce these stem cells into becoming oligodendrocytes, the ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... gradual extinction of cold-loving species, and the European land ... from the University of Kassel in Germany and the ... that human-induced temperature increases over a 40-year period in ... the near extinction of the local land leech Xerobdella ...
... have long known that the human body runs like clockwork, ... of light and darkness. Now a team of researchers is ... activity, which could allow them to predict optimal timing for ... solar day and relieve psychosocial stress. In short, ...
... showing that dog-walking in bushland significantly reduces bird ... against the practice in sensitive bushland and conservation ... the ecological impacts of dog-walking have remained subjective ... But the first clear evidence that birds ...
Cached Biology News:Role reversal as humans suck life out of leeches 2Researchers developing device to predict proper light exposure for human health 2Researchers developing device to predict proper light exposure for human health 3A dog in the hand scares birds in the bush 2
...
...
... White solid. PROTECT FROM LIGHT. ... sulfanamido-benzbromarone compound that acts as a ... of PTP1B (IC 50 = ... PTP1B 403 and PTP1B 298 ...
...
Biology Products: